These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 34423909)
1. Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study. Rosenthal YS; Schwartz N; Sagy I; Pavlovsky L Arthritis Rheumatol; 2022 Feb; 74(2):237-243. PubMed ID: 34423909 [TBL] [Abstract][Full Text] [Related]
2. Does biologic therapy impact the development of PsA among patients with psoriasis? Meer E; Merola JF; Fitzsimmons R; Love TJ; Wang S; Shin D; Chen Y; Xie S; Choi H; Zhang Y; Scher JU; Ritchlin CT; Gelfand JM; Ogdie A Ann Rheum Dis; 2022 Jan; 81(1):80-86. PubMed ID: 34615637 [TBL] [Abstract][Full Text] [Related]
3. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018 [TBL] [Abstract][Full Text] [Related]
4. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904 [TBL] [Abstract][Full Text] [Related]
5. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965 [TBL] [Abstract][Full Text] [Related]
6. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study. Tillett W; Ogdie A; Passey A; Gorecki P RMD Open; 2023 Jan; 9(1):. PubMed ID: 36650006 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network. Tsai SHL; Yang CY; Huo AP; Wei JC J Am Acad Dermatol; 2024 Nov; 91(5):889-895. PubMed ID: 39079603 [TBL] [Abstract][Full Text] [Related]
8. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Singla S; Putman M; Liew J; Gordon K Lancet Rheumatol; 2023 Apr; 5(4):e200-e207. PubMed ID: 38251522 [TBL] [Abstract][Full Text] [Related]
9. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. Pina Vegas L; Penso L; Claudepierre P; Sbidian E JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735 [TBL] [Abstract][Full Text] [Related]
10. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Eder L; Haddad A; Rosen CF; Lee KA; Chandran V; Cook R; Gladman DD Arthritis Rheumatol; 2016 Apr; 68(4):915-23. PubMed ID: 26555117 [TBL] [Abstract][Full Text] [Related]
11. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Wilson FC; Icen M; Crowson CS; McEvoy MT; Gabriel SE; Kremers HM Arthritis Rheum; 2009 Feb; 61(2):233-9. PubMed ID: 19177544 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study. Wei JC; Shi LH; Huang JY; Wu XF; Wu R; Chiou JY J Rheumatol; 2018 Mar; 45(3):385-392. PubMed ID: 29335350 [TBL] [Abstract][Full Text] [Related]
13. Treatment persistence of biologics among patients with psoriatic arthritis. Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410 [TBL] [Abstract][Full Text] [Related]
14. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Baumrin E; Van Voorhees A; Garg A; Feldman SR; Merola JF J Am Acad Dermatol; 2019 Jul; 81(1):102-110. PubMed ID: 30885757 [TBL] [Abstract][Full Text] [Related]
15. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Green A; Shaddick G; Charlton R; Snowball J; Nightingale A; Smith C; Tillett W; McHugh N; Br J Dermatol; 2020 Mar; 182(3):714-720. PubMed ID: 31209855 [TBL] [Abstract][Full Text] [Related]
16. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Lebwohl MG; Kavanaugh A; Armstrong AW; Van Voorhees AS Am J Clin Dermatol; 2016 Feb; 17(1):87-97. PubMed ID: 26718712 [TBL] [Abstract][Full Text] [Related]
18. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368 [TBL] [Abstract][Full Text] [Related]
19. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221 [TBL] [Abstract][Full Text] [Related]
20. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Tveit KS; Duvetorp A; Østergaard M; Skov L; Danielsen K; Iversen L; Seifert O J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):340-354. PubMed ID: 30242921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]